Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 25, 2008 Brian Orelli	Affymetrix Astounds, in the Worst Way After taking a beating last quarter, biochip maker Affymetrix got pounded again in the second quarter, as its turnaround from the lows of 2006 fizzled out.
The Motley Fool November 12, 2008 Brian Orelli	Affymetrix Gets Specific The biochip maker announces that it will acquire privately held Panomics for $73 million in cash.
The Motley Fool October 22, 2008 Jim Mueller	Illuminating Illumina Did the DNA analysis equipment maker miss, meet, or beat expectations? Well, it's complicated.
The Motley Fool February 6, 2008 Brian Orelli	Insatiable Illumina Revenue is way up at Illumina, but can the company keep it going looking forward?
The Motley Fool April 25, 2008 Brian Orelli	Affymetrix Learns About Inertia Slower sales of its older chips drag down growth.
The Motley Fool July 26, 2007 Brian Orelli	Affymetrix Advances New products and services should help Affymetrix regain market share. Yesterday, the company even announced a small second-quarter profit.
The Motley Fool April 24, 2008 Brian Orelli	Illumina Ignites This biochip maker is on fire.
The Motley Fool October 24, 2007 Brian Orelli	Illumina's Illuminating Results There was stellar revenue growth, but margins and stock compensations pulled the bottom line down.
The Motley Fool October 25, 2007 Brian Orelli	Turnaround at Affymetrix Affymetrix announces it is continuing its turnaround from an abysmal 2006 with another strong quarter.
The Motley Fool February 4, 2009 Brian Orelli	43% Growth! Yee-Haw! Illumina rocks another quarter.
The Motley Fool July 24, 2008 Brian Orelli	Illumina Polishes Its Biochips There's very little to complain about in Illumina's earnings report. In this market, you'll see few investors grumbling about double-digit growth.
The Motley Fool January 11, 2008 Brian Orelli	Biochip Packaging: Some Settling May Occur Biochip maker Illumina settles its disputes about patents with Affymetrix.
The Motley Fool July 28, 2010 Brian Orelli	Now There's an Illuminating Idea Helping your customers sell more of your product makes a lot of sense.
The Motley Fool October 20, 2008 Brian Orelli	Foolish Forecast: Will Pfizer Flounder Through Another Quarter? Pharmaceutical giant Pfizer releases earnings tomorrow morning. Let's take a look at what the numbers might say and, more importantly, what management might be able to say to get this stock out of its drug-induced coma.
The Motley Fool March 18, 2008 Brian Orelli	The Nuts and Bolts of Drug Research Merck just released a pair of papers detailing the network of proteins that are linked to obesity, but the pharmaceutical company won't benefit much financially from its studies. So who will?
The Motley Fool October 21, 2008 Brian Orelli	The World Is Saving Pfizer The pharma company experienced a double-digit decrease in U.S. sales in the third quarter. Ouch.
The Motley Fool August 6, 2008 Brian Orelli	Illumina Grabs Some Cash With biochip maker Illumina hitting 52-week highs, it seems inevitable that the company would do a secondary offering to grab some cash -- about $300 million, as it turns out.
The Motley Fool January 28, 2005 Karl Thiel	Affymetrix Raking in the Chips The life sciences research chip maker is enjoying green pastures in the gene business. The company announced fourth-quarter revenues and profits that handily beat consensus expectations, and then gave an upbeat view of 2005.
The Motley Fool November 17, 2008 Rich Smith	This Just In: Upgrades and Downgrades Bank of America analysts aren't terribly impressed with most drug companies. But they did give thumbs up to two.
The Motley Fool February 8, 2010 Brian Orelli	An Earnings Surprise of an Unusual Kind Illumina beats management's own preliminary revenue announcement.
The Motley Fool April 22, 2009 Brian Orelli	Illuminating Stock Option Problems Illumina's stock options are getting a little ridiculous. This problem was pointed out in the third quarter last year, and it doesn't seem to be going away.
The Motley Fool September 28, 2005 Stephen D. Simpson	Affymetrix Stumbles Again Though the company was one of the only genomics plays to escape the bubble with a real business and a solid market cap, Affymetrix's stock seemed poised to take a serious hit Wednesday for the second time in about three months.
Bio-IT World July 2005 Johan Bostrom	Affymetrix to Acquire ParAllele The companies have been working together for the past two years, with Affymetrix using ParAllele's assay technology with the Affymetrix GeneChip technology. Affymetrix expects to strengthen its assay R&D capabilities and add knowledge in specific assay capabilities through the acquisition.
The Motley Fool July 22, 2009 Brian Orelli	Levering the Genome Lower revenue can't stop Illumina from turning in a good bottom line.
The Motley Fool July 25, 2007 Brian Orelli	Shiny Happy Illumina Illumina, which makes chips that can distinguish one million different genes, announced another stellar quarter. That makes eight in a row.
The Motley Fool April 27, 2007 Brian Orelli	Making Money Off Your Competitors Affymetrix is looking appealing with a few new products and potential revenues from an unlikely source. Investors, take note.
The Motley Fool August 7, 2006 Stephen D. Simpson	Affymetrix: Price Always Matters Affymetrix has legit technology, but that doesn't mean it has infinite value for investors.
Bio-IT World February 2007 Robert M. Frederickson	Scramble for CodeLink Customers GE Healthcare has quietly announced that it will stop production of the popular CodeLink array system in 2007. The news was not a complete surprise to some users of the system who felt the company had been backing away from the platform.
The Motley Fool July 23, 2011	Affymetrix Earnings Preview Affymetrix will unveil its latest earnings on Wednesday, July 27.
The Motley Fool April 27, 2011 Brian Orelli	Illuminating the Growth Competition in the DNA sequencing market may be heating up, but 47% growth for Illumina isn't too shabby.
Chemistry World November 21, 2013 Phillip Broadwith	Rapid DNA sequencing cleared for the clinic The approval covers Illumina's MiSeqDx instrument, together with two diagnostic assay kits for cystic fibrosis that run on it, and a kit that allows clinical labs to develop their own diagnostic tests.
The Motley Fool August 30, 2010 Seth Jayson	Is Affymetrix Growing or Slowing? Is Affymetrix sending any warning signs? Take a look at its accounts receivable and days sales outstanding to find out.
The Motley Fool July 22, 2005 Stephen D. Simpson	Big Miss Afflicts Affymetrix Gee-whiz technology doesn't always mean gee-whiz growth. While the facilitator of genetics research and drug development enjoyed has recovered significantly from its lows, long-term investors saw another market thrashing on a disappointing outlook.
The Motley Fool October 28, 2009 Brian Orelli	Ugly, but Still Built for Growth It continues to be a tale of two business segments for Illumina, with sales from the consumables used in its sequencing machines more than doubling, while its array business remains down considerably.
The Motley Fool August 12, 2009 Brian Orelli	The Next Big Thing Is Not Right in Front of You Perhaps the fastest evolving technology right now is found in DNA sequencing.
The Motley Fool April 5, 2005 Stephen D. Simpson	Pfizer Pfaces Its Pfuture Analysts and investors seem happy with Pfizer's long-term strategy. Should they be?
The Motley Fool May 4, 2010 Brian Orelli	Earnings Growth Trumps Revenue Growth, Except Here A solid quarter for Pfizer, but is there more in the tank?
The Motley Fool January 14, 2010 Brian Orelli	$1,000 Genomes, Here We Come Illumina jumps on news of its $10,000 genome.
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today.
Chemistry World May 29, 2014 Hepeng Jia	Chinese-made DNA sequencer aims to challenge foreign dominance With an independently developed next-generation DNA sequencer, Chinese scientists are aiming to challenge the dominance of international players in the world's fastest growing genome sequencing market.
BusinessWeek April 25, 2005 Gene G. Marcial	Affymetrix: A Lab Boost The GeneChip can reduce the risk of adverse reactions to drugs by checking the recipient's DNA against the drug's profile. Some people are optimistic about the company's stock.
BusinessWeek February 20, 2006 Gene G. Marcial	Fast Growth At Illumina Is In The Genes The company has become a rising star in the complex analysis of gene variation, and the stock shows it.
The Motley Fool April 24, 2006 John Bluis	Affymetrix Gets Chipped Again The woes continue for Affymetrix, the leading provider of high-density microarray products. Investors must decide if this is a management issue -- as indeed it appears to be.
The Motley Fool February 10, 2006 Brian Gorman	Pfizer in Pflux The company is working on its transition, but things still look fairly murky for investors.
The Motley Fool December 18, 2008 Brian Orelli	Best Stock for 2009: Pfizer Pfizer's languishing stock price has made the company so much more attractive; it could see a breakout in 2009.
The Motley Fool October 20, 2006 Brian Lawler	Pfizer Keeps Fighting If Pfizer's management can succeed on its cost-savings initiatives and maintain the high single digits of earnings-per-share growth that it expects in 2007-2008, then Pfizer may make a good investment for those willing to wait for the company's new drugs to bring back higher growth.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull The drug giant has ample firepower. The current company valuation largely ignores Pfizer's upside potential past 2008.
The Motley Fool April 20, 2007 Ryan Fuhrmann	Discerning Pfizer's Pfuture The company is undergoing a transformation, but that doesn't mean it isn't worth a look from investors.
Chemistry World August 22, 2014 Phillip Broadwith	Illumina targets cancer diagnostics Genetic sequencing heavyweight Illumina has partnered with three major pharmaceutical firms in a bid to develop a universal sequencing-based oncology test system.
The Motley Fool June 13, 2008 Brian Orelli	China Medical Passes the Test China Medical's revenue was up an impressive 74% year over year.